By now, you will have gathered that we are even more worried about the direction of UKHSA, its actions, its secrecy, and its complete lack of accountability.
We focused on the difficult job of understanding the whys and wherefores of the UKHSA’s purchase of more than 5 million doses of an Influenza H5 pandemic vaccine.
There are many uncertainties, starting from which vaccine and its content, the effects, the apparent absence of an open competitive tendering process and the UKHSA’s refusal to disclose the cost and any risk-benefit analysis they may have carried out.
Even more worrying is the fact that TTE had sight of a response from the UKHSA indicating that the purchased vaccines are “expected” to diminish mortality.
The series relating our efforts to get more information from the UKHSA and MHRA is currently running on TTE. As we promised, we are updating the documents we receive from both the MHRA and UKHSA under FOIA. Our readers who are working with us have provided other sources of …
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.